These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage. Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763 [TBL] [Abstract][Full Text] [Related]
4. The Roles of SPOP in DNA Damage Response and DNA Replication. Maekawa M; Higashiyama S Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023230 [TBL] [Abstract][Full Text] [Related]
6. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression. Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355 [TBL] [Abstract][Full Text] [Related]
7. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371 [TBL] [Abstract][Full Text] [Related]
8. Mre11 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage Complexes. Hoa NN; Shimizu T; Zhou ZW; Wang ZQ; Deshpande RA; Paull TT; Akter S; Tsuda M; Furuta R; Tsutsui K; Takeda S; Sasanuma H Mol Cell; 2016 Nov; 64(3):580-592. PubMed ID: 27814490 [TBL] [Abstract][Full Text] [Related]
9. Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes. Lee KC; Swan RL; Sondka Z; Padget K; Cowell IG; Austin CA Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011940 [TBL] [Abstract][Full Text] [Related]
10. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer. Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495 [TBL] [Abstract][Full Text] [Related]
11. Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis. Jin X; Qing S; Li Q; Zhuang H; Shen L; Li J; Qi H; Lin T; Lin Z; Wang J; Cao X; Yang J; Ma Q; Cong L; Xi Y; Fang S; Meng X; Gong Z; Ye M; Wang S; Wang C; Gao K Nucleic Acids Res; 2021 Jul; 49(12):6788-6803. PubMed ID: 34133717 [TBL] [Abstract][Full Text] [Related]
12. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706 [TBL] [Abstract][Full Text] [Related]
13. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719 [TBL] [Abstract][Full Text] [Related]
14. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein. Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305 [TBL] [Abstract][Full Text] [Related]
15. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics. Wang H; Barbieri CE; He J; Gao Y; Shi T; Wu C; Schepmoes AA; Fillmore TL; Chae SS; Huang D; Mosquera JM; Qian WJ; Smith RD; Srivastava S; Kagan J; Camp DG; Rodland KD; Rubin MA; Liu T J Transl Med; 2017 Aug; 15(1):175. PubMed ID: 28810879 [TBL] [Abstract][Full Text] [Related]
16. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway. Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929 [TBL] [Abstract][Full Text] [Related]
17. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants. Zhang P; Gao K; Tang Y; Jin X; An J; Yu H; Wang H; Zhang Y; Wang D; Huang H; Yu L; Wang C Hum Mutat; 2014 Sep; 35(9):1142-51. PubMed ID: 24990631 [TBL] [Abstract][Full Text] [Related]
18. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822 [TBL] [Abstract][Full Text] [Related]
19. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. An J; Wang C; Deng Y; Yu L; Huang H Cell Rep; 2014 Feb; 6(4):657-69. PubMed ID: 24508459 [TBL] [Abstract][Full Text] [Related]
20. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Theurillat JP; Udeshi ND; Errington WJ; Svinkina T; Baca SC; Pop M; Wild PJ; Blattner M; Groner AC; Rubin MA; Moch H; Prive GG; Carr SA; Garraway LA Science; 2014 Oct; 346(6205):85-89. PubMed ID: 25278611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]